Clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology Formosa Pharmaceuticals (6838.TWO) announced on Monday that it has entered into an exclusive licensing agreement with Apotex Inc., a pharmaceutical corporation, for the commercialization rights of clobetasol propionate ophthalmic suspension, 0.05% (APP13007) in Canada.
Approved by the US Food and Drug Administration (FDA) on 4 March 2024, APP13007 is a patented medicine for treating post-ocular surgery inflammation and pain.
The licensing deal involves an upfront payment and milestone payments contingent on regulatory and sales achievements. Derived from Formosa Pharma's proprietary APNT nanoparticle formulation, APP13007 offers a convenient twice-daily dosing regimen over 14 days, showing superior efficacy in Phase 3 trials.
Entering a market valued at approximately CAD50m and growing at 5% annually, APP13007 addresses the needs of an estimated 500,000 ocular surgeries in Canada each year.
(USD1=CAD1.38)
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Scinai Immunotherapeutics reports positive results in psoriasis study
Johnson & Johnson acquires Yellow Jersey Therapeutics
Spine BioPharma, signs agreement with Ensol BioSciences
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
Delta-Fly Pharma initiates Phase III trial for lung cancer drug DFP-14323